A randomized, double-blind, placebo-controlled, parallel group, safety, efficacy and pharmacodynamic study of basmisanil (RO5186582) in adults with severe motor impairment following an ischemic stroke
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Basmisanil (Primary)
- Indications Neurological disorders
- Focus Adverse reactions; Therapeutic Use
- Acronyms STROBE
- Sponsors Roche
- 04 Jan 2018 Status changed from recruiting to discontinued.
- 13 Mar 2017 Planned End Date changed from 1 Oct 2018 to 26 Sep 2018.
- 13 Mar 2017 Planned primary completion date changed from 1 Oct 2018 to 26 Sep 2018.